


A STEREOCONTROLLED SYNTHESIS OF C-4' ALKYLATED PYRIMIDINE C-NUCLEOSIDES¹

T. Sato, M. Watanabe, and R. Noyori*

Department of Chemistry, Nagoya University, Chikusa, Nagoya 464, Japan

Summary: A general, stereocontrolled synthesis of pyrimidine C-nucleosides possessing an alkyl group at the C-1' or C-4' position is outlined.

In the area of nucleoside synthesis, a variety of modifications of the carbohydrate moiety have been investigated in the hope of obtaining therapeutically useful agents. Powerful anti-trypanosomal property of nucleocidin (I)² has stimulated interest in devising efficient methods allowing substituent incorporation at the C-4' position,³ only very few modifications at this position have been reported.⁴ Disclosed herein is the first stereospecific synthesis of C-4' alkylated pyrimidine C-nucleosides.




I


The bicyclic ketone IIa⁵ was obtained in 70% yield by the Fe₂(CO)₉-aided [3 + 4] cyclo-coupling reaction between $\alpha, \alpha, \alpha', \alpha'$ -tetrabromoacetone and 2-methylfuran (Fe₂(CO)₉:halo ketone:furan = 1.5:2:1, benzene, 60 °C, 5 h),⁶ followed by treatment with Zn/Cu couple in methanol saturated with NH₄Cl (25 °C, 1 h). In place of Fe₂(CO)₉, Zn/Ag couple may be employed (60% yield).⁷ The unsaturated ketone IIa was then allowed to react with 30% H₂O₂ (2 equiv) and a catalytic amount of OsO₄ (ca. 1 mol %) in acetone-tert-butyl alcohol-ether (10:1:1 v/v) (25 °C, 12 h) and the crude product was treated with acetone-CuSO₄ (large excess) containing p-CH₃C₆H₄SO₃H (25 °C, 12 h), leading to the acetonide IIIa⁸ in a stereospecific manner (53% yield). When this compound was subjected to the Baeyer-Villiger oxidation with

$\text{CF}_3\text{CO}_2\text{H}$ (3 equiv) in CH_2Cl_2 containing Na_2HPO_4 and $\text{EDTA}\cdot 2\text{Na}$ ($0-20^\circ\text{C}$, 10 h), there were obtained the regioisomeric lactones IVa⁹ and Va¹⁰ in a 53:47 ratio (90% combined yield).


Treatment of the bicyclic lactone IVa with excess *tert*-butoxybis(dimethylamino)methane in DMF (70°C , 3 h) gave the dimethylaminomethylene derivative VIa¹¹ in 70% yield. Conversion of VIa to an uracil VIIa¹² was accomplished by heating VIa with urea (10 equiv) in 1.6 N




II




III





IV




V




VI

VII, R'-R' = C(CH₃)₂
VIII, R' = H


IX




X (HCl salt)




XI



XII



XIII



XIV (HCl salt)

a: R = CH₃

b: R = (CH₂)₄CH₃

ethanolic C_2H_5ONa (reflux, 2 h, 31%). The assignment of β configuration of the uracil appendage was made on the basis of the 1H NMR spectrum, particularly the spin-spin coupling constant, $J_{1',2'} = 6.5$ Hz,¹³ and chemical shift of the isopropylidene methyls, δ 1.40 and 1.66 ($\Delta\delta = 0.26$ ppm).¹⁴ Finally, VIIa was exposed to 10% HCl in methanol (25 °C, 15 min) to form 4'-methylpseudouridine (VIIIa).^{15,16} Preparation of 4'-methyl-2-thiopseudouridine (IXa) was effected by heating VIa with thiourea in 1.4 N ethanolic C_2H_5ONa (80 °C, 2 h), followed by dil HCl treatment (75%). When VIa was condensed with guanidine and then the isopropylidene protective group was removed, 4'-methylpseudoisocytidine (Xa) was produced in 64% yield.

When 2-pentylfuran was used as a C_4 component in the initial [3 + 4] cyclocoupling reaction, the bicyclic ketone IIb was obtained. This compound was also transformed to the corresponding pyrimidine \underline{C} -nucleosides according to similar synthetic procedures.

Elaboration of heterocycles onto XI was achieved less effectively (10–20% yield) because of the severe steric hindrance of the alkyl group. In any event, this bicyclic lactone route marks the first synthesis of C-1' alkylated \underline{C} -nucleosides.¹⁷

Acknowledgment: This work was supported in part by the Kurata Science Foundation.

REFERENCES AND NOTES

1. \underline{C} -Nucleoside Synthesis. VI. Part V: T. Sato, M. Watanabe, and R. Noyori, Chem. Lett., 1297 (1978).
2. R. J. Suhadolnik, "Nucleoside Antibiotics", Wiley--Interscience, New York, N.Y., 1970, pp 246--256.
3. I. D. Jenkins, J. P. H. Verheyden, and J. G. Moffatt, J. Am. Chem. Soc., 93, 4323 (1971).
4. J. P. H. Verheyden, I. D. Jenkins, G. R. Owen, S. D. Dimitrijevič, C. M. Richards, P. C. Srivastava, N. Le-Hong, and J. G. Moffatt, Ann. N.Y. Acad. Sci., 255, 151 (1975); G. R. Owen, J. P. H. Verheyden, and J. G. Moffatt, J. Org. Chem., 41, 3010 (1976); R. Youssefyeh, D. Tegg, J. P. H. Verheyden, G. H. Jones, and J. G. Moffatt, Tetrahedron Lett., 435 (1977); J. A. Secrist III and W. J. Winter, Jr., J. Am. Chem. Soc., 100, 2554 (1978).
5. Reviews: R. Noyori, Ann. N.Y. Acad. Sci., 295, 225 (1977); R. Noyori, Acc. Chem. Res., 12, 61 (1979).
6. IR (neat) 1718 cm^{-1} . NMR ($CDCl_3$) δ 1.50 (s, CH_3), 2.1–2.9 (m, CH_2), 5.06 (ddd, $J = 5.0, 1.8, 1.2$ Hz, $OCHCH_2C=O$), 6.05 (d, $J = 5.8$ Hz, $OC(CH_3)CH=CH$), 6.20 (dd, $J = 5.8, 1.8$ Hz, $OCHCH=CH$).
7. T. Sato and R. Noyori, Bull. Chem. Soc. Jpn., 51, 2745 (1978).
8. Mp 76–77 °C. IR ($CHCl_3$) 1719 cm^{-1} . NMR ($CDCl_3$, pseudouridine numbering) δ 1.30 and

- 1.52 (s, isopropylidene CH₃), 1.42 (s, CH₃), 2.2–2.8 (m, H₅_a, H₅_b), 4.30 (d, H₂_a), 4.51 (d, H₃_a), 4.54 (dd, H₁_a); $J_{1',2'} = \text{ca. } 0 \text{ Hz}$, $J_{2',3'} = 5.7 \text{ Hz}$, $J_{1',5a} = 1.8 \text{ Hz}$, $J_{1',5b} = 5.2 \text{ Hz}$.
9. Mp 100–102 °C. IR (CHCl₃) 1735 cm⁻¹. NMR (C₆D₆) δ 1.01 (s, CH₃), 1.07 and 1.40 (s, isopropylidene CH₃), 2.25 (dd, H₅_a), 2.45 (dd, H₅_b), 3.38 (d, H₅_a), 3.56 (d, H₅_b), 3.93 (dd, H₁_a), 4.41 (d, H₂_a), 4.48 (d, H₃_a); $J_{1',2'} = \text{ca. } 0 \text{ Hz}$, $J_{2',3'} = 6.0 \text{ Hz}$, $J_{5'a,5'b} = 14.0 \text{ Hz}$, $J_{1',5a} = 2.9 \text{ Hz}$, $J_{1',5b} = 4.1 \text{ Hz}$, $J_{5a,5b} = 15.5 \text{ Hz}$.
10. Mp 100–101 °C. IR (CHCl₃) 1735 cm⁻¹. NMR (C₆D₆) δ 1.05 and 1.38 (s, isopropylidene CH₃), 1.16 (s, CH₃), 2.34 (d, H₅_a), 2.54 (d, H₅_b), 3.36 (dd, H₅_a), 3.60 (d, H₅_b), 3.91 (d, H₄_a), 4.33 (d, H₂_a), 4.67 (d, H₃_a); $J_{2',3'} = 6.0 \text{ Hz}$, $J_{3',4'} = J_{4',5'b} = \text{ca. } 0 \text{ Hz}$, $J_{4',5'a} = 4.0 \text{ Hz}$, $J_{5'a,5'b} = 13.8 \text{ Hz}$, $J_{5a,5b} = 16.0 \text{ Hz}$.
11. Mp 118–120 °C. IR (CHCl₃) 1680, 1590 cm⁻¹. UV λ_{max} (CH₃OH) 297 nm (ε 19800). The NMR spectrum (CDCl₃) exhibited characteristic signals at δ 1.26 (s, CH₃), 1.33 and 1.51 (s, isopropylidene CH₃), 2.94 and 3.11 (N(CH₃)₂, 33:67 ratio), 6.67 and 7.34 (=CH, 33:67 ratio).
12. Mp 200–205 °C. NMR (pyridine-d₅) δ 1.40 and 1.66 (s, isopropylidene CH₃), 1.50 (s, CH₃), 3.79 (d, H₅_a), 3.95 (d, H₅_b), 5.07 (d, H₃_a), 5.15 (d, H₁_a), 5.44 (dd, H₂_a), 7.92 (s, H₆); $J_{1',2'} = 6.5 \text{ Hz}$, $J_{2',3'} = 5.5 \text{ Hz}$, $J_{5'a,5'b} = 11.0 \text{ Hz}$. UV λ_{max} (CH₃OH) 266 nm (ε 7230), λ_{max} (0.1 N NaOH) 285 nm (ε 7510).
13. H. Ohrui, G. H. Jones, J. G. Moffatt, M. L. Maddox, A. T. Christensen, and S. K. Byram, *J. Am. Chem. Soc.*, 97, 4602 (1975); H. Ohrui and S. Emoto, *J. Org. Chem.*, 42, 1951 (1977).
14. J.-L. Imbach, *Ann. N.Y. Acad. Sci.*, 255, 177 (1975).
15. Mp 226–228 °C. NMR (pyridine-d₅) δ 1.69 (s, CH₃), 3.90 (d, H₅_a), 4.08 (d, H₅_b), 4.87 (m, H₃_a), 5.26 (m, H₁_a and H₂_a), 6.32 (br, OH), 7.98 (s, H₆), 12.50 and 13.20 (br, NH); $J_{5'a,5'b} = 11.5 \text{ Hz}$. UV λ_{max} (CH₃OH) 264 nm (ε 7760), λ_{max} (0.1 HCl) 264 nm (ε 7510), λ_{max} (0.1 N NaOH) 286 nm (ε 7540).
16. All compounds described herein are racemic. Stable compounds gave correct elemental analysis and/or exact mass spectral data.
17. For example, XIIIb UV λ_{max} (CH₃OH) 215 nm (ε 10910), 277 (14540), 291 (13190, s), λ_{max} (0.1 N HCl) 213 nm (ε 7280, s), 273 (8440), 295 (6160, s), λ_{max} (0.1 N NaOH) 220 nm (ε 9340, s), 262 (9420), 297 (4590, s). XI Va UV λ_{max} (CH₃OH) 222 nm (ε 9490), 262 (6290), 300 (1030, s), λ_{max} (0.1 N HCl) 221 nm (ε 8680), 262 (6450), λ_{max} (0.1 N NaOH) 230 nm (ε 11030), 278 (8250). The NMR spectra were consistent with the structures assigned.